Clinical and Radiographic Success of MTA vs Biodentine

Summary

The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.

Timeline

Start

2021-11-12

Primary completion

2026-08-01

Completion

2026-12-01

Drugs

Indications